Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Marc Ferrante(Universitair Ziekenhuis Leuven), Geert D’Haens(Amsterdam UMC Location University of Amsterdam), Remo Panaccione(University of Calgary), Kori Wallace(AbbVie (United States)), Marla C. Dubinsky(New Leaders), Peter Bossuyt(Imelda Hospital), W. Rachel Duan(AbbVie (United States)), Kristina Kligys(Northwestern University), Alexandra Song(AbbVie (United States)), William J. Sandborn(Mayo Clinic), Valerie Pivorunas(AbbVie (United States)), Tadakazu Hisamatsu(Kyorin University), Anne Robinson(AbbVie (United States)), Julián Panés(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Laurent Peyrin‐Biroulet(Inserm), Silvio Danese(Università Cattolica del Sacro Cuore), Brian G. Feagan(Western University), David T. Rubin(University of California System), Jasmina Kalabic(AbbVie (Germany)), James O. Lindsay(European Crohn's and Colitis Organisation), Edward V. Loftus(Mayo Clinic), Stefan Schreiber(Goethe University Frankfurt), Yinuo Pang(AbbVie (United States)), Bidan Huang(AbbVie (United States)), Zhihua Ran(Shanghai Jiao Tong University), Sofie Berg(AbbVie (United States)), Xiaomei Liao(AbbVie (United States)), Filip Baert(AZ Delta), Ezequiel Neimark(AbbVie (United States)), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Allen Lim(University of Alberta)
Cited by 312
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k